
Journeys Metabolic helps health systems and providers reverse metabolic disease through an at-home, physician-developed digital program that improves clinical outcomes and quality scores. It delivers a 4–6 month, HITRUST-certified, EHR-interoperable digital therapeutic combining AI-enabled precision pathways, computer vision food tracking, and a proprietary Biosense biomarker for fat oxidation to personalize care. The platform functions as a B2B digital health solution (digital therapeutic / clinical SaaS) and integrates with provider workflows and population health systems to automate enrollment and reporting for ACOs and value-based care models. The company reports real-world outcomes across thousands of patients, including average weight loss, A1c reductions, and NAFLD improvements, positioning it for deployment at scale across health systems and accountable care organizations.

Journeys Metabolic helps health systems and providers reverse metabolic disease through an at-home, physician-developed digital program that improves clinical outcomes and quality scores. It delivers a 4–6 month, HITRUST-certified, EHR-interoperable digital therapeutic combining AI-enabled precision pathways, computer vision food tracking, and a proprietary Biosense biomarker for fat oxidation to personalize care. The platform functions as a B2B digital health solution (digital therapeutic / clinical SaaS) and integrates with provider workflows and population health systems to automate enrollment and reporting for ACOs and value-based care models. The company reports real-world outcomes across thousands of patients, including average weight loss, A1c reductions, and NAFLD improvements, positioning it for deployment at scale across health systems and accountable care organizations.
What they do: B2B digital therapeutic that helps health systems reverse metabolic disease via an at-home, physician-developed program
Product highlights: 4–6 month, HITRUST-certified, EHR-interoperable program with AI-enabled pathways, computer-vision food tracking, and a proprietary Biosense biomarker
Go-to-market: Integrates with provider workflows and population health systems for ACOs and value-based care
Founded / legal name: Founded 2018 (legal name: Readout, Inc.)
Funding: Multiple early rounds; Seed announced Feb 22, 2023 (lead: Missouri Technology Corporation)
Headquarters: St. Louis, Missouri, United States
Metabolic disease management and value-based care enablement for health systems and providers
2018
Biotechnology
Crunchbase lists a Seed round announced Feb 22, 2023; company has multiple early-stage financings and four reported funding events including non-equity assistance entries.
“Missouri Technology Corporation lead on Seed; other named investors/backers include BioGenerator, Creative Destruction Lab (CDL), New York Angels, Synchrony Bio, and iSelect Fund.”